0001214659-22-004087.txt : 20220317
0001214659-22-004087.hdr.sgml : 20220317
20220317175949
ACCESSION NUMBER: 0001214659-22-004087
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220315
FILED AS OF DATE: 20220317
DATE AS OF CHANGE: 20220317
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Amado Rafael
CENTRAL INDEX KEY: 0001662119
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 22750170
MAIL ADDRESS:
STREET 1: 5 ASHWOOD LANE
CITY: MALVERN
STATE: PA
ZIP: 19435
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
marketforms-55824.xml
PRIMARY DOCUMENT
X0306
4
2022-03-15
0001737287
Allogene Therapeutics, Inc.
ALLO
0001662119
Amado Rafael
210 EAST GRAND AVE
SOUTH SAN FRANCISCO
CA
94080
false
true
false
false
EVP of R&D and CMO
Common Stock
2022-03-15
4
S
false
5169
7.7090
D
320119
D
Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.69 to $7.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Includes 1360 shares of the Issuer's common stock acquired by the reporting person on March 15, 2022 pursuant to an employee stock purchase program.
Veer Bhavnagri as attorney-in-fact for Rafael Amado
2022-03-17